Salud financiera de hoja de balance de Innovative Pharmaceutical Biotech

Salud financiera controles de criterios 0/6

Innovative Pharmaceutical Biotech tiene un patrimonio de los accionistas total de HK$333.1M y una deuda total de HK$1.0B, lo que sitúa su ratio deuda-patrimonio en 312.7%. Sus activos y pasivos totales son HK$1.4B y HK$1.0B respectivamente.

Información clave

312.7%

Ratio deuda-patrimonio

HK$1.04b

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	HK$862.00k
Patrimonio	HK$333.07m
Total pasivo	HK$1.05b
Activos totales	HK$1.38b

Actualizaciones recientes sobre salud financiera

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (HK$8.8M) de 399 no cubren sus pasivos a corto plazo (HK$378.0M).

Pasivo a largo plazo: Los activos a corto plazo (HK$8.8M) de 399 no cubren sus pasivos a largo plazo (HK$671.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 399 (312.4%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 399 ha crecido de 77.9% a 312.7% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de 399 es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de 399 sobre su deuda están bien cubiertos por el EBIT.

Salud financiera de hoja de balance de Innovative Pharmaceutical Biotech

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Recent updates

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera